NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
28 August 2007 - 12:00AM
PR Newswire (US)
HUBBARD, Ohio, Aug. 27 /PRNewswire-FirstCall/ -- NanoLogix, Inc.
(OTC:NNLX) is pleased to announce that Chris R. Novak, Esq. has
joined the company as Director of Intellectual Property. In
addition, we wish to announce that major advances have been made in
the rapid detection of Anthrax utilizing the NanoLogix
BioNanoChannel(TM) Device. Mr. Novak has over seven years'
experience as an intellectual property counsel in a wide range of
high tech industries including the position of Corporate
Intellectual Property Counsel of IDT (Integrated Device Technology,
Inc.), a NASDAQ 100 semiconductor company with sales of over $800
million a year. Mr. Novak has a Bachelor of Science in Mechanical
Engineering and a Juris Doctorate, both awarded by Marquette
University. He also holds a Master of Science Degree in Electrical
Engineering from Cal Poly State University. Mr. Novak is licensed
for the practice of law in California, Colorado, and Wisconsin and
the United States Patent and Trademark Office (USPTO) and is
preparing for admission to the Ohio Bar. In addition to his
experience as a patent attorney, Mr. Novak worked as an engineer
for high-tech companies for ten years. "Mr. Novak will represent
NanoLogix as our dedicated intellectual property counsel and manage
the expansion and protection of our technologies through patents
and other methods. NanoLogix's key asset value is its impressive
intellectual property portfolio," said Vice President of Strategic
Partnering, Dana Allen. "We are pleased to welcome Chris to the
Company in this newly- created role." "I believe the revolutionary
and practical ideas being developed at NanoLogix will have a major
impact on the biotechnology and energy fields," said Director of IP
Chris Novak, Esq. "We plan to protect these ideas to the fullest
extent, and turn these ideas into marketplace realities that will
sharply increase revenues." In another significant development,
Nanologix has been working on a request from the United States
Department of Defense to explore the potential of rapid
determination of Anthrax spore viability, utilizing NanoLogix's
BioNanoChannel(TM) (BNC) technology. There appears to be an
opportunity to determine the viability and persistence of Anthrax
spores much faster than current methods due to the unique rapid
culturing aspects of the BNC technology. "Superb progress has been
made in our research efforts simulating Anthrax spore growth
through the use of non-hazardous spores. This research has the
potential to immediately translate to the ability to conduct rapid
Anthrax viability testing," said CEO Bret Barnhizer. "We have been
impressed with the Department of Defense's dedication to finding
the best solution for the security of our country in the event of a
biological attack. We look forward to making a major contribution
in this area by providing a method by which the government is able
to determine the effectiveness of their decontamination efforts in
hours rather than days." About NanoLogix, Inc. NanoLogix is an
industry innovator in the research, development, and
commercialization of nano-biotechnologies, applications and
processes. The Company has developed and owns or has rights to 31
patents related to various medical technologies, 5 of which also
have hydrogen-generation aspects. In the past year the Company has
filed an additional 28 patent applications for discoveries related
to hydrogen bioreactors, medical testing, and innovative medical
treatments potentially related to leukemia and sepsis. NanoLogix is
presently operating a hydrogen bioreactor at Welch's Food.
NanoLogix-developed patents are used to design and market
diagnostic test kits for use in early detection of the bacteria
present in infectious and noninfectious human diseases such as
tuberculosis, pneumonia, HIV/AIDS, cancer, and cystic fibrosis. The
company also owns a patent for the non-toxic induction of apoptosis
('cell suicide') for the treatment of cancer. BioNanoChannel is a
Trademark of NanoLogix, Inc. For more information on the Company,
visit http://www.nanologixinc.com/. This press release contains
statements, which may constitute "forward- looking statements"
within the meaning of the Securities Act of 1933 and the Securities
Exchange Act of 1934, as amended by the Private Securities
Litigation Reform Act of 1995. Those statements include statements
regarding the intent, belief or current expectations of NanoLogix,
Inc., and members of its management as well as the assumptions on
which such statements are based. Prospective investors are
cautioned that any such forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties, and that actual results may differ materially from
those contemplated by such forward-looking statements. The Company
undertakes no obligation to update or revise forward-looking
statements to reflect changed assumptions, the occurrence of
unanticipated events or changes to future operating results.
Contact: Investor Relations Bret Barnhizer, CEO Telephone:
330-534-0800 E-mail: DATASOURCE: NanoLogix, Inc. CONTACT: Investor
Relations, Bret Barnhizer, CEO of NanoLogix, Inc., +1-330-534-0800,
Web site: http://www.nanologixinc.com/
Copyright